Skip to main content
Erschienen in: Current Allergy and Asthma Reports 3/2011

01.06.2011

Guillain-Barré Syndrome: Modern Theories of Etiology

verfasst von: Todd A. Hardy, Stefan Blum, Pamela A. McCombe, Stephen W. Reddel

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Guillain-Barré syndrome (GBS) is a classic failure of the immune system with a life-threatening attack upon a critical self-component. The active phase of the disease is short, concordant with the latency of a primary adaptive immune response. Triggers for GBS include infection and (rarely) vaccination; cross-reactivity between infectious and neural epitopes has been well demonstrated, particularly for Campylobacter jejuni and motor axonal forms of GBS in which non-protein gangliosides are antigenic. Most people are probably exposed to a GBS trigger, but only rarely does the disease develop. We propose that GBS illustrates competing determinants of the immune system’s decision about whether to mount a response, and that in unlucky affected individuals, co-presentation of cross-reactive antigens with danger signals activating pattern-recognition receptors overcomes normal self-recognition such that a primary response is initiated that attacks the nerve. Then, in most cases of GBS, the response rapidly turns off, and second attacks rarely occur. This suggests active restoration of tolerance, and specific privileged site attributes of nerve and declining danger signals as the trigger wanes may contribute to this restoration. Standard immunosuppression has not been effective in GBS. We suggest this is because immune tolerance is already being restored by the time such therapies are initiated. This in turn suggests that improvements in GBS outcomes are likely to come from better protection of the nerve cells under attack while normal resumption of tolerance is permitted to proceed rather than exploring more aggressive immunosuppressive approaches.
Literatur
1.
Zurück zum Zitat Zinkernagel R. On observing and analyzing disease versus signals. Nat Immunol. 2007;8:8–10.PubMedCrossRef Zinkernagel R. On observing and analyzing disease versus signals. Nat Immunol. 2007;8:8–10.PubMedCrossRef
2.
Zurück zum Zitat Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–13.PubMedCrossRef Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–13.PubMedCrossRef
3.
Zurück zum Zitat van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.PubMedCrossRef van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.PubMedCrossRef
5.
Zurück zum Zitat Ruts L, Drenthen J, Jacobs BC, Van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74:1680–6.PubMedCrossRef Ruts L, Drenthen J, Jacobs BC, Van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74:1680–6.PubMedCrossRef
6.
Zurück zum Zitat Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:105–23.PubMed Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:105–23.PubMed
7.
Zurück zum Zitat Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.PubMedCrossRef Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.PubMedCrossRef
9.
Zurück zum Zitat Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf. 2009;32:309–23.PubMedCrossRef Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf. 2009;32:309–23.PubMedCrossRef
10.
Zurück zum Zitat Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine. 1969;48:173–215.PubMedCrossRef Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine. 1969;48:173–215.PubMedCrossRef
11.
Zurück zum Zitat Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–56.PubMedCrossRef Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–56.PubMedCrossRef
12.
Zurück zum Zitat Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1431–9.PubMedCrossRef Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1431–9.PubMedCrossRef
13.
Zurück zum Zitat McCombe PA, Csurhes PA. T cells from patients with Guillain-Barre syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci. 2010;17:537–8.PubMedCrossRef McCombe PA, Csurhes PA. T cells from patients with Guillain-Barre syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci. 2010;17:537–8.PubMedCrossRef
14.
Zurück zum Zitat Chi L-J, Wang H-B, Zhang Y, Wang W-Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol. 2007;192:206–14.PubMedCrossRef Chi L-J, Wang H-B, Zhang Y, Wang W-Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol. 2007;192:206–14.PubMedCrossRef
15.
Zurück zum Zitat Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci. 2008;15:1031–5.PubMedCrossRef Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci. 2008;15:1031–5.PubMedCrossRef
16.
Zurück zum Zitat Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRef Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRef
17.
Zurück zum Zitat Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22.PubMedCrossRef Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22.PubMedCrossRef
18.
Zurück zum Zitat Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115–26.PubMedCrossRef Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115–26.PubMedCrossRef
19.
Zurück zum Zitat McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42.PubMedCrossRef McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42.PubMedCrossRef
20.
Zurück zum Zitat Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39:17–28.PubMedCrossRef Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39:17–28.PubMedCrossRef
21.
Zurück zum Zitat Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies. Neurology. 1999;53:2122–7.PubMed Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies. Neurology. 1999;53:2122–7.PubMed
22.
Zurück zum Zitat Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol. 1999;45:168–73.PubMedCrossRef Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol. 1999;45:168–73.PubMedCrossRef
23.
Zurück zum Zitat Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.PubMedCrossRef Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.PubMedCrossRef
24.
Zurück zum Zitat Lopez PHH, Zhang G, Bianchet MA, et al. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008;131:1926–39.PubMedCrossRef Lopez PHH, Zhang G, Bianchet MA, et al. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008;131:1926–39.PubMedCrossRef
25.
Zurück zum Zitat Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: Mini-review. J Neuroimmunol. 2010;223:5–12.PubMedCrossRef Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: Mini-review. J Neuroimmunol. 2010;223:5–12.PubMedCrossRef
26.
Zurück zum Zitat Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol. 2008;21:540–6.PubMedCrossRef Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol. 2008;21:540–6.PubMedCrossRef
27.
Zurück zum Zitat Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635–44.PubMedCrossRef Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635–44.PubMedCrossRef
28.
Zurück zum Zitat • Halstead SK, Zitman FMP, Humphreys PD, et al: Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197–1208. This study demonstrated a realistic therapy for possible trials in human GBS. PubMedCrossRef • Halstead SK, Zitman FMP, Humphreys PD, et al: Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197–1208. This study demonstrated a realistic therapy for possible trials in human GBS. PubMedCrossRef
29.
Zurück zum Zitat Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci. 1999;168:121–6.PubMedCrossRef Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci. 1999;168:121–6.PubMedCrossRef
30.
Zurück zum Zitat Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81:1157–63.PubMedCrossRef Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81:1157–63.PubMedCrossRef
31.
Zurück zum Zitat Madrid RE, Wiśniewski HM. Axonal degeneration in demyelinating disorders. J Neurocytol. 1977;6:103–17.PubMedCrossRef Madrid RE, Wiśniewski HM. Axonal degeneration in demyelinating disorders. J Neurocytol. 1977;6:103–17.PubMedCrossRef
32.
Zurück zum Zitat Sobottka B, Harrer MD, Ziegler U, et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol. 2009;175:1160–6.PubMedCrossRef Sobottka B, Harrer MD, Ziegler U, et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol. 2009;175:1160–6.PubMedCrossRef
33.
Zurück zum Zitat Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–9.PubMedCrossRef Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–9.PubMedCrossRef
34.
Zurück zum Zitat Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Nat. 1964;98:129–49.CrossRef Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Nat. 1964;98:129–49.CrossRef
35.
Zurück zum Zitat Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst. 2007;12:238–49.PubMedCrossRef Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst. 2007;12:238–49.PubMedCrossRef
36.
Zurück zum Zitat van Belkum A, van den Braak N, Godschalk P, et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med. 2001;7:752–3.PubMedCrossRef van Belkum A, van den Braak N, Godschalk P, et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med. 2001;7:752–3.PubMedCrossRef
37.
Zurück zum Zitat Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology. 2005;65:1376–81.PubMedCrossRef Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology. 2005;65:1376–81.PubMedCrossRef
38.
Zurück zum Zitat Halstead SK, O’Hanlon GM, Humphreys PD, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–23.PubMedCrossRef Halstead SK, O’Hanlon GM, Humphreys PD, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–23.PubMedCrossRef
39.
Zurück zum Zitat Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38:218–24.PubMedCrossRef Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38:218–24.PubMedCrossRef
40.
Zurück zum Zitat Shamshiev A, Donda A, Prigozy TI, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity. 2000;13:255–64.PubMedCrossRef Shamshiev A, Donda A, Prigozy TI, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity. 2000;13:255–64.PubMedCrossRef
41.
Zurück zum Zitat Shamshiev A, Donda A, Carena I, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol. 1999;29:1667–75.PubMedCrossRef Shamshiev A, Donda A, Carena I, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol. 1999;29:1667–75.PubMedCrossRef
42.
Zurück zum Zitat Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig. 2004;114:1379–88.PubMed Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig. 2004;114:1379–88.PubMed
43.
Zurück zum Zitat Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated T cells cause focal breakdown of the blood–nerve barrier. Brain. 1995;118:857–68.PubMedCrossRef Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated T cells cause focal breakdown of the blood–nerve barrier. Brain. 1995;118:857–68.PubMedCrossRef
44.
Zurück zum Zitat Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood–nerve barrier to circulating antibody. Ann Neurol. 1995;37:467–75.PubMedCrossRef Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood–nerve barrier to circulating antibody. Ann Neurol. 1995;37:467–75.PubMedCrossRef
45.
Zurück zum Zitat Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.PubMedCrossRef Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.PubMedCrossRef
46.
Zurück zum Zitat • Kuitwaard K, van Koningsveld R, Ruts L, et al: Recurrent Guillain Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2009, 80:56–59. This article confirmed the low rate of recurrent GBS and demonstrated that the few patients who do have recurrences have other features of autoimmunity, and that the standard on-off case does not. CrossRef • Kuitwaard K, van Koningsveld R, Ruts L, et al: Recurrent Guillain Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2009, 80:56–59. This article confirmed the low rate of recurrent GBS and demonstrated that the few patients who do have recurrences have other features of autoimmunity, and that the standard on-off case does not. CrossRef
47.
Zurück zum Zitat • Steiner I, Rosenberg G, Wirguin I: Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barre syndrome? Clin Exp Immunol 2010. This article presents an interesting related hypothesis that suggests more of a role for transient immunosuppression as an initiating feature but also deals well with the reasons why GBS is not a typical autoimmune disease. • Steiner I, Rosenberg G, Wirguin I: Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barre syndrome? Clin Exp Immunol 2010. This article presents an interesting related hypothesis that suggests more of a role for transient immunosuppression as an initiating feature but also deals well with the reasons why GBS is not a typical autoimmune disease.
48.
Zurück zum Zitat Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007;8:11–3.PubMedCrossRef Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007;8:11–3.PubMedCrossRef
Metadaten
Titel
Guillain-Barré Syndrome: Modern Theories of Etiology
verfasst von
Todd A. Hardy
Stefan Blum
Pamela A. McCombe
Stephen W. Reddel
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 3/2011
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0190-y

Weitere Artikel der Ausgabe 3/2011

Current Allergy and Asthma Reports 3/2011 Zur Ausgabe

ReviewPaper

The Watery Eye

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.